Примери за използване на Based on a population pharmacokinetic на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Elderly Based on a population pharmacokinetic analysis, no dose adjustment of Tecentriq is required in patients≥ 65 years of age(see sections 4.8 and 5.1).
Based on a population pharmacokinetic analysis, no dose adjustment is necessary for patients with calculated creatinine clearance(CrCL) values≥ 30 mL/min(estimated by the Cockcroft and Gault formula).
Age(18-73 years) had no clinically meaningful effect on the pharmacokinetics of simeprevir based on a population pharmacokinetic analysis(n= 21,
Based on a population pharmacokinetic analysis(age range 18- 81 years)
The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to<
Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab as monotherapy at subcutaneous doses of either 75 mg Q2W or 150 mg Q2W.
Based on a population pharmacokinetic analysis of patients receiving up to 24 mg lenvatinib once daily,
In addition, based on a population pharmacokinetic analysis that included 183 patients with advanced cancer, where 73 patients
Based on a population pharmacokinetic(PK) analysis,
Based on a population pharmacokinetic analysis that included 74 subjects with mild hepatic impairment,
Based on a population pharmacokinetic analysis including patients with normal renal function
Based on a population pharmacokinetic analysis that included 160 breast cancer patients with normal hepatic function
Based on a population pharmacokinetic analysis of the PEGASUS study the median ticagrelor Cmax was 391 ng/ml
Based on a population pharmacokinetic analysis in 183 patients with cancer(50 male
Based on a population pharmacokinetic analysis in 82 immunocompromised patients aged 2 to< 12 years**Based on a population pharmacokinetic analysis in 47 immunocompromised patients aged 2 to< 12 years.
Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I
Gender does not have an effect on the exposure of cobimetinib, based on a population pharmacokinetic analysis including 210 women and 277 men.
Age had no clinically relevant effect on the pharmacokinetics of albiglutide based on a population pharmacokinetic analysis of subjects aged 24-83 years(see section 4.2).
Based on a population pharmacokinetic analysis, the central volume of distribution was 12.56 L.
Based on a population pharmacokinetic analysis, race had no impact on alirocumab pharmacokinetics.